Novo Nordisk Partners With JDRF In Type 1 Diabetes Push
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk will conduct early research around the underlying autoimmune process central to type 1 diabetes in a partnership with JDRF; the company simultaneously opened its Type 1 Diabetes R&D Center in Seattle.
You may also be interested in...
Selecta/JDRF Collaboration Seeks Vaccine To Prevent Or Treat Type 1 Diabetes
JDRF will provide milestone-based financial support toward preclinical proof of concept for a tolerogenic vaccine candidate.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.